Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.

An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...

As a urologist I'm seeing teenagers with bladders so damaged they need the kind of major reconstructive surgery I'd normally ...

Urinary incontinence (UI) is the involuntary loss of urine. Just having a UI “accident” occasionally may not require ...

Feline Lower Urinary Tract Disease is most common in cats aged about four to eight years old. Read more at straitstimes.com. Read more at straitstimes.com.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) demonstrates efficacy ...

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a conditional marketing authorization in the EU for Anktiva to treat adults with ...

1 Department of Urology, The People’s Hospital of Leshan, Leshan, China 2 Department of Urology, Affiliated Hospital of Yunnan University (Second People’s Hospital of Yunnan Province, Ophthalmic ...

(NewsNation) — Can cancer be killed? Billionaire Dr. Patrick Soon-Shiong, who also owns the LA Times and co-owns the Los Angeles Lakers, says yes. Soon-Shiong’s ImmunityBio developed Anktiva, a ...

As the researchers behind Pfizer and Astellas' Padcev and Merck's Keytruda have taken victory laps on the heels of the positive readout of Keynote-905 study—also known as EV-303—terms like ...

Bladder cancer ranks among the ten most common types of cancer worldwide. The main treatment is bladder removal surgery, and despite advances in systemic therapies, recurrence is frequent in the most ...